Please assess the completion status of the following clinical trial:

Trial Title: Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* neonates ≤ 30 days of postnatal age at time of operation~* birthweight \> 2.5 kg~* gestational age at birth ≥ 35 weeks~* Patients requiring cardiac surgery who are expected to remain intubated in the CCIU for \> 48 hours~* informed consent by parent or guardian~* approval by treating critical care staff physician~Exclusion Criteria:~* patients with heterotaxy or pre-existing renal or abdominal pathology (eg. preoperative diagnosis of NEC).~* need for ECMO after repair within the study period (data up to that point will be recorded and analyzed).~* Parent refusal of formula for purposes of study~* Patient on vasopressin or norepinephrine infusion~* Parent or legal guardian refuse consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: 30 Days
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 1 will receive continuous nasogastric formula feeding at time 1 and NPO at time 2 (12 hours later).
- 2 (Type: EXPERIMENTAL): The initial observation period of the study begins in the postoperative period (time 0) after the patient arrives in the Cardiac Critical Care Unit and calibration of the monitors with initial clinically indicated baseline bloodwork is completed. Eligible patients will be randomized when the clinical decision to feed is made (by the treating team) to one of the two treatment arms. Patients in arm 2 will receive NPO at time 1 and crossover to continuous nasogastric formula feeding at time 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).